q-bio.QM 92-10, 92C50
A Reanalysis of the FDA's Benefit-Risk Assessment of Moderna's mRNA-1273 COVID Vaccine: For 18-25-Year-Old Males, Risks Exceeded Benefits Relative to Hospitalizations
Paul S. Bourdon Ram Duriseti H. Christian Gromoll Dyana K. Dalton Kevin Bardosh Allison E. Krug